Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by TheTerminator1on May 18, 2021 9:07am
53 Views
Post# 33220913

RE:RE:RE:RE:RE:UK Covid deaths yesterday

RE:RE:RE:RE:RE:UK Covid deaths yesterdayAgain with the smart azz attirude...The man who's shyt don't think

The Bucillamine trials results will have a lot more value thatn you pretend it will...The results willl show the full power of Bucillamine and will not only be limited to the Covid-19 virus

And who said anything about Gobal approval...Stop putting words in my mouth.

I will more time on the rest of your post,you sound like a idiot without a home

Longs should not rely on you and stick to RVV who has a lot more going than a Bucillamine trial

It is obvious to me that all you thing about is yourself and making taking the people's money

Poor little man, i pitty you!



1ottrunner wrote:

First, I didn't realize RVV was trying to get Global approval?

The sooner you accept the Covid angle of this company has come to an end, and management does too, the better.

You do realize the current SP is the result of the promise outside of Covid, yes?  You see Term, Covid may be around forever, but so is the vaccine.

How about this, Bucillamine gets approval today, those with mild to moderate symptoms can now take it if they want, one of the choices available for mild to moderate.  Is that 5000 patients a day?  I'm being extremely optimistic.  6 months from now is that 1000 patients per day?

Rather than post rediculous speculation about the billions you are going to make as an investor, How about you lay out exactly what you believe the result of EUA today would be.

Patients per day:
Patients per year forward:
RVV revenues from BUC:

I await your response.

 

TheTerminator1 wrote: We have a long way to go before the world is completely immunized from this virus...Don't hold your breath,you will not make it.
 

 

1ottrunner wrote: Welcome to NOW!

The vaccine is working, RVV can't help the past and it's too late to help the now.

TheTerminator1 wrote: It's just a regular flu says the man!!!!!!

Tell that to all those who died from a lack of oxygen and to all those Long-Haulers who are still suffering many side effects 3,4,5,6,7 or more months after the came down with the virus

1ottrunner wrote: 5

historically this is the about the same as a regular flu.

The Covid vaccine will be included in the regular flu shot, the pandemic is coming to a close in developed nations.

If Buccilamine proves to be a success it might be used to help 5000 ailing patients per year in Canada and possibly 50,000 in the US.

That might be worth a million dollars of yearly revenue.

 

 

 




<< Previous
Bullboard Posts
Next >>